Market Overview

UPDATE: Piper Jaffray Raises PT to $11 on ISIS Pharmaceuticals on KYNAMRO Approval

Related ISIS
Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016
Benzinga's Top Initiations

Piper Jaffray maintained ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) with a Neutral rating and raised the price target from $9.00 to $11.00.

Piper Jaffray said, "The FDA approved KYNAMRO for Homozygous Familial Hypercholesterolemia (HoFH). As expected, the approval comes with a Boxed Warning for liver toxicity and a REMS program. ISIS is required to conduct 4 post marketing studies. This approval comes in the wake of the recent negative CHMP opinion for KYNAMRO's marketing authorization application (MAA) and therefore serves as an important validation of ISIS's antisense technology. We maintain our Neutral rating and are increasing our price target to $11 from $9 due to a reduced discount rate following KYNAMRO approval."

ISIS Pharmaceuticals closed at $13.38 on Tuesday.

Latest Ratings for ISIS

Dec 2015Wells FargoInitiates Coverage onOutperform
Nov 2015Goldman SachsInitiates Coverage onNeutral
Nov 2015BarclaysMaintainsEqual-Weight

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (ISIS)

View Comments and Join the Discussion!